Alongside observational and academic studies, we run a range of clinical trials. Please see below the full list of currently open trials and contact details if you are interested in finding out more.


Phase III trial looking at the use of sublingual apomorphine in patients with advanced Parkinson’s Disease. Sponsor: Sunovion.
Currently recruiting. Contact:


DUOdopa/Duopa in Patients with Advanced Parkinson’s Disease (PD) – a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE).

A global multicentre single-arm observational study to assess the effectiveness of levodopa/carbidopa intestinal gel treatment on OFF time as reported by advanced PD patients. The study period is split as [1] baseline, [2] treatment with PEG-J vistit and titration period of up to 14 days, and [3] up to 36 months observations.


Phase 3, 4-week, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Participants are randomised to ampreloxetine or placebo and will recieve a single, oral daily dose of active or placebo drug for 4 weeks.


A 52-week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects with Parkinson’s disease. This phase 3 open label study is using this new form of LD/CD (ABBV-951) which is a novel form of administering the medication.